HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Structural basis for therapeutic intervention of uPA/uPAR system.

Abstract
Urokinase-type plasminogen activator (uPA) is one of the two physiological serine proteases responsible for the activation of plasminongen to plasmin. uPA activity is regulated by its inhibitors (PAI-1 and PAI-2) and its receptor (uPAR), and an expanding list of their interacting proteins. In addition to plasminogen activation, this system also plays important roles in the regulation of many cellular processes including cell proliferation, adhesion and migration. It is beyond reasonable doubt that this enzyme system plays a central role in tumor biology and represents a high potential target for therapeutic intervention of tumor growth and metastasis. During the past fifteen years, crystal structures of uPA and its inhibitors have facilitated the development of uPA inhibitors. Many crystal structures of proteins in the uPA/uPAR system have also been reported recently, especially a series of structures of uPAR and its complexes with vitronectin and uPA, facilitating the development and evaluation of uPAR inhibitors. Recent progress on uPA inhibitors will be summarized in this article. The unique structural features and the druggable potentials of these new structures will also be discussed.
AuthorsJacky Chi Ki Ngo, Longguang Jiang, Zhonghui Lin, Cai Yuan, Zhuo Chen, Xu Zhang, Haiyang Yu, Jundong Wang, Lin Lin, Mingdong Huang
JournalCurrent drug targets (Curr Drug Targets) Vol. 12 Issue 12 Pg. 1729-43 (Nov 2011) ISSN: 1873-5592 [Electronic] United Arab Emirates
PMID21707478 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Antineoplastic Agents
  • Peptides, Cyclic
  • Receptors, Urokinase Plasminogen Activator
  • Somatomedins
  • upain-1 peptide
  • Urokinase-Type Plasminogen Activator
Topics
  • Animals
  • Antineoplastic Agents (chemistry, pharmacokinetics, pharmacology, therapeutic use)
  • Biological Availability
  • Humans
  • Molecular Targeted Therapy
  • Peptides, Cyclic (chemistry, pharmacokinetics, pharmacology, therapeutic use)
  • Protein Conformation
  • Protein Interaction Domains and Motifs
  • Receptors, Urokinase Plasminogen Activator (antagonists & inhibitors, chemistry, metabolism)
  • Signal Transduction (drug effects)
  • Somatomedins (chemistry, metabolism, pharmacology, therapeutic use)
  • Translational Research, Biomedical
  • Urokinase-Type Plasminogen Activator (antagonists & inhibitors, chemistry, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: